GE Healthcare Manufactures Single-Use Consumables in China
GE Healthcare will collaborate with Wego Pharmaceutical in China for local production and supply of GE Healthcare’s Fortem single-use consumables.
GE Healthcare will manufacture single-use consumables for bioprocessing in Weihai, China, in collaboration with Wego Pharmaceutical, GE Healthcare announced in a Nov. 7, 2018 press release. This collaboration will decrease product delivery times for Chinese biopharmaceutical companies, enhance customer support locally, and increase access to a wide range of standard and custom single-use products.
The first single-use consumables produced at Wego’s manufacturing facility will be available in 2018, with continued offerings released throughout 2019. All products will be manufactured using Fortem, GE Healthcare’s single-use platform film, which simplifies customer validation and approval processes by incorporating GE’s full range of bioprocessing systems.
“We are excited to play a critical role within the Chinese biopharma industry by ensuring efficient lead times and security of supply, which ultimately helps the local manufacturers to serve patients faster. China continues to lead in the adoption of innovative single-use biomanufacturing solutions, including GE Healthcare’s end-to-end biomanufacturing solutions KUBio and FlexFactory,” said Olivier Loeillot, general manager, BioProcess, GE Healthcare Life Sciences, in a company press release.
Source: GE Healthcare
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
